| Cobimetinib studied in …STUDIED_INderived87 of 87show fewer |
|---|
| → studied in | NCT04302025Phase 2 · recruiting A Study of Multiple Therapies in Biomarker-selected Participants With Resectable Stages IB-III Non-small Cell Lung Cancer (NSCLC) · 87 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04931342Phase 2 · active not recruiting A Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors · 87 trials list this drug (22 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04005690early Phase 1 · recruiting Targeted Pathway Inhibition in Patients With Pancreatic Cancer · 87 trials list this drug (22 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Ductal Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03178552Phase 2/Phase 3 · active not recruiting A Study to Evaluate the Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) · 87 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03600701Phase 2 · active not recruiting Atezolizumab and Cobimetinib in Treating Patients With Metastatic, Recurrent, or Refractory Non-small Cell Lung Cancer · 87 trials list this drug (22 active) | — | — | Malignant Lung Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03281369Phase 1/Phase 2 · terminated A Study of Multiple Immunotherapy-Based Treatment Combinations in Patients With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Cancer (G/GEJ) or Esophageal Cancer (Morpheus-Gastric and Esophageal Cancer) · 87 trials list this drug (22 active) | — | — | Esophageal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03181100Phase 2 · active not recruiting Atezolizumab With Chemotherapy in Treating Patients With Anaplastic or Poorly Differentiated Thyroid Cancer · 87 trials list this drug (22 active) | — | — | Thyroid Gland Anaplastic Carcinoma,Thyroid Gland Carcinoma,Poorly Differentiated Thyroid Gland Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03768063Phase 3 · active not recruiting A Study in Patients Previously Enrolled in a Genentech and/or F. Hoffmann-La Roche Ltd Sponsored Atezolizumab Study · 87 trials list this drug (22 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05034627Phase 1 · completed Calaspargase Pegol-Mnkl and Cobimetinib for the Treatment of Locally Advanced or Metastatic Pancreatic Cancer · 87 trials list this drug (22 active) | — | — | Malignant Pancreatic Neoplasm,Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04409639Phase 2 · active not recruiting Cobimetinib in Newly Diagnosed or HMA-treated CMML Patients With RAS Pathway Mutations · 87 trials list this drug (22 active) | — | — | Chronic Myelomonocytic Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04835805Phase 1 · active not recruiting A Study to Evaluate the Safety and Activity of Belvarafenib as a Single Agent and in Combination With Either Cobimetinib or Cobimetinib Plus Nivolumab in Patients With NRAS-mutant Advanced Melanoma. · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03175432Phase 2 · active not recruiting Bevacizumab and Atezolizumab With or Without Cobimetinib in Treating Patients With Untreated Melanoma Brain Metastases · 87 trials list this drug (22 active) | — | — | Melanoma,Intracranial Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06813079Phase 2 · recruiting Using Tumor Models to Determine Treatments · 87 trials list this drug (22 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04722575Phase 2 · active not recruiting Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-risk, Resectable Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03202316Phase 2 · active not recruiting Atezolizumab, Cobimetinib, and Eribulin in Treating Patients With Chemotherapy Resistant Metastatic Inflammatory Breast Cancer · 87 trials list this drug (22 active) | — | — | Breast Inflammatory Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03224767Phase 2 · active not recruiting Vemurafenib and Cobimetinib in Treating Patients With BRAF V600E Mutation Positive Craniopharyngioma · 87 trials list this drug (22 active) | — | — | Papillary Craniopharyngioma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05691504Phase 1 · active not recruiting Testing the Combination of APG-1252 (Pelcitoclax) and Cobimetinib in Recurrent Ovarian and Endometrial Cancers · 87 trials list this drug (22 active) | — | — | Primary Peritoneal Carcinoma,Endometrial Carcinoma,Fallopian Tube Carcinoma+1 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03337698Phase 1/Phase 2 · terminated A Study Of Multiple Immunotherapy-Based Treatment Combinations In Participants With Metastatic Non-Small Cell Lung Cancer (Morpheus- Non-Small Cell Lung Cancer) · 87 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03202940Phase 1/Phase 2 · active not recruiting A Phase IB/II Study of Alectinib Combined With Cobimetinib in Advanced ALK-Rearranged (ALK+) NSCLC · 87 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05441514Phase 1 · completed Enasidenib in Combination With Cobimetinib for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia · 87 trials list this drug (22 active) | — | — | Acute Myeloid Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03554083Phase 2 · completed Vemurafenib, Cobimetinib, Atezolizumab, and Tiragolumab in Treating Patients With High-Risk Stage III Melanoma · 87 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04216953Phase 1/Phase 2 · completed MEK Inhibitor and a PDL1 Inhibitor Patients With Locally Advanced and/or Metastatic Soft Tissue Sarcoma · 87 trials list this drug (22 active) | — | — | Soft Tissue Sarcoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02721459Phase 1 · active not recruiting XL888 + Vemurafenib + Cobimetinib for Unresectable BRAF Mutated Stage III/IV Melanoma · 87 trials list this drug (22 active) | — | — | Malignant Skin Neoplasm,Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT06440850Phase 2 · recruiting Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation · 87 trials list this drug (22 active) | — | — | Thyroid Gland Follicular Carcinoma,Thyroid Gland Oncocytic Carcinoma,Thyroid Gland Papillary Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04109456Phase 1 · completed IN10018 Monotherapy and Combination Therapy for Metastatic Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05768178Phase 2/Phase 3 · recruiting DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. · 87 trials list this drug (22 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Solid Neoplasm,Melanoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03193190Phase 1/Phase 2 · completed A Study of Multiple Immunotherapy-Based Treatment Combinations in Participants With Metastatic Pancreatic Ductal Adenocarcinoma (Morpheus-Pancreatic Cancer) · 87 trials list this drug (22 active) | — | — | Pancreatic Adenocarcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03498521Phase 2 · completed A Phase II Randomized Study Comparing the Efficacy and Safety of Targeted Therapy or Cancer Immunotherapy Versus Platinum-Based Chemotherapy in Patients With Cancer of Unknown Primary Site · 87 trials list this drug (22 active) | — | — | Malignant Neoplasm of Unknown Primary | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02060188Phase 2 · completed A Study of Nivolumab Alone or Nivolumab Combination Therapy in Colon Cancer That Has Come Back or Has Spread · 87 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04079179Phase 2 · recruiting Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders · 87 trials list this drug (22 active) | — | — | Erdheim-Chester Disease,Histiocytic Sarcoma,Juvenile Xanthogranuloma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02908672Phase 3 · completed A Study of Atezolizumab Plus Cobimetinib and Vemurafenib Versus Placebo Plus Cobimetinib and Vemurafenib in Previously Untreated BRAFv600 Mutation-Positive Patients With Metastatic or Unresectable Locally Advanced Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03108131Phase 2 · completed Cobimetinib and Atezolizumab in Treating Participants With Advanced or Refractory Rare Tumors · 87 trials list this drug (22 active) | — | — | Malignant Neoplasm,Mucinous Adenocarcinoma,Skin Squamous Cell Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04941287Phase 2 · active not recruiting Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer · 87 trials list this drug (22 active) | — | — | Liver Carcinoma,Intrahepatic Cholangiocarcinoma,Malignant Gallbladder Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02902029Phase 2 · completed Evaluating the Efficacy and Safety of a Sequencing Schedule of Cobimetinib Plus Vemurafenib Followed by Immunotherapy With an Anti- PD-L1 Antibody in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05260684completed Comparative Effectiveness of Targeted Therapies in BRAF Positive Metastatic Melanoma in the US · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04551521Phase 2 · completed CRAFT: The NCT-PMO-1602 Phase II Trial · 87 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01928394Phase 1/Phase 2 · completed A Study of Nivolumab by Itself or Nivolumab Combined With Ipilimumab in Patients With Advanced or Metastatic Solid Tumors · 87 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04214418Phase 1/Phase 2 · terminated Study of Combination Therapy With the MEK Inhibitor, Cobimetinib, Immune Checkpoint Blockade, Atezolizumab, and the AUTOphagy Inhibitor, Hydroxychloroquine in KRAS-mutated Advanced Malignancies · 87 trials list this drug (22 active) | — | — | Malignant Digestive System Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04185831Phase 2 · unknown A MolEcularly Guided Anti-Cancer Drug Off-Label Trial · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02091141Phase 2 · completed My Pathway: A Study Evaluating Herceptin/Perjeta, Tarceva, Zelboraf/Cotellic, Erivedge, Alecensa, and Tecentriq Treatment Targeted Against Certain Molecular Alterations in Participants With Advanced Solid Tumors · 87 trials list this drug (22 active) | — | — | Neoplasm,Solid Neoplasm,Malignant Bladder Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03101254Phase 1/Phase 2 · completed LY3022855 With BRAF/MEK Inhibition in Patients With Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05159245Phase 2 · recruiting The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs · 87 trials list this drug (22 active) | — | — | Hematopoietic and Lymphoid Cell Neoplasm,Malignant Neoplasm,Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03395899Phase 2 · completed Pre-operative Immunotherapy Combination Strategies in Breast Cancer · 87 trials list this drug (22 active) | — | — | Breast Neoplasm,Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04190628Phase 1 · terminated Safety and Tolerability of ABM-1310 in Patients With Advanced Solid Tumors · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02291289Phase 2 · completed A Study of Biomarker-Driven Therapy in Metastatic Colorectal Cancer (mCRC) · 87 trials list this drug (22 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03625141Phase 2 · completed A Study Evaluating the Safety and Efficacy of Cobimetinib Plus Atezolizumab in BRAFV600 Wild-type Melanoma With Central Nervous System Metastases and Cobimetinib Plus Atezolizumab and Vemurafenib in BRAFV600 Mutation-positive Melanoma With Central Nervous System Metastases · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03201458Phase 2 · completed Atezolizumab With or Without Cobimetinib in Treating Patients With Metastatic Bile Duct Cancer That Cannot Be Removed by Surgery or Gallbladder Cancer · 87 trials list this drug (22 active) | — | — | Intrahepatic Cholangiocarcinoma,Cholangiocarcinoma,Gallbladder Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03878524Phase 1 · terminated Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial · 87 trials list this drug (22 active) | — | — | Hematopoietic and Lymphatic System Neoplasm,Hematopoietic and Lymphoid Cell Neoplasm,Malignant Solid Neoplasm+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT05238831early Phase 1 · withdrawn SMMART Adaptive Clinical Treatment (ACT) Trial · 87 trials list this drug (22 active) | — | — | Malignant Solid Neoplasm,Sarcoma,Breast Carcinoma+2 | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04591431Phase 2 · unknown The Rome Trial From Histology to Target: the Road to Personalize Target Therapy and Immunotherapy · 87 trials list this drug (22 active) | — | — | Malignant Breast Neoplasm,Malignant Digestive System Neoplasm,Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03430947Phase 2 · terminated Vemurafenib Plus Cobimetinib After Radiosurgery in Patients With BRAF-mutant Melanoma Brain Metastases · 87 trials list this drug (22 active) | — | — | Melanoma,Brain Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03695380Phase 1 · completed A Clinical Study of Cobimetinib Administered in Combination With Niraparib, With or Without Atezolizumab to Patients With Advanced Platinum-sensitive Ovarian Cancer · 87 trials list this drug (22 active) | — | — | Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03363867Phase 2 · unknown BEACON - ABC in Recurrent Platinum Resistant HGSOC · 87 trials list this drug (22 active) | — | — | Primary Peritoneal Carcinoma,Malignant Fallopian Tube Neoplasm,Malignant Ovarian Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03989115Phase 1/Phase 2 · completed Dose-Esc/Exp RMC4630 & Cobi in Relapsed/Refractory Solid Tumors & RMC4630& Osi in EGFR+ Locally Adv/Meta NSCLC · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT04801966NA · terminated Safety and Oversight of the Individually Tailored Treatment Approach: A Novel Pilot Study · 87 trials list this drug (22 active) | — | — | Malignant Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02322814Phase 2 · terminated A Study of Cobimetinib Plus Paclitaxel, Cobimetinib Plus Atezolizumab Plus Paclitaxel, or Cobimetinib Plus Atezolizumab Plus Nab-Paclitaxel as Initial Treatment for Participants With Triple-Negative Breast Cancer That Has Spread · 87 trials list this drug (22 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03312530Phase 1/Phase 2 · completed A Study of Cobimetinib Administered as Single Agent and in Combination With Venetoclax, With or Without Atezolizumab, in Participants With Relapsed and Refractory Multiple Myeloma · 87 trials list this drug (22 active) | — | — | Multiple Myeloma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02036086Phase 2 · unknown Study of Neo-adjuvant Use of Vemurafenib Plus Cobimetinib for BRAF Mutant Melanoma With Palpable Lymph Node Metastases · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03273153Phase 3 · terminated A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma · 87 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02639546Phase 1/Phase 2 · completed Safety and Pharmacokinetics of Cobimetinib in Pediatric and Young Adult Participants With Previously Treated Solid Tumors · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01689519Phase 3 · completed A Study Comparing Vemurafenib Versus Vemurafenib Plus Cobimetinib in Participants With Metastatic Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01959633Phase 1/Phase 2 · completed Vemurafenib Plus Cobimetinib Plus PEG-interferon in Advanced Melanoma Patients Harboring the V600BRAF Mutation · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02670044Phase 1 · completed A Study of Venetoclax in Combination With Cobimetinib and Venetoclax in Combination With Idasanutlin in Patients With Relapsed or Refractory Acute Myeloid Leukemia Who Are Not Eligible for Cytotoxic Therapy · 87 trials list this drug (22 active) | — | — | Leukemia | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02818023Phase 1 · terminated Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03178851Phase 1 · completed Cobimetinib (Targeted Therapy) Plus Atezolizumab (Immunotherapy) in Participants With Advanced Melanoma Whose Cancer Has Worsened During or After Treatment With Previous Immunotherapy and Atezolizumab Monotherapy in Participants With Previously Untreated Advanced Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03566485Phase 1/Phase 2 · terminated Atezolizumab and Cobimetinib or Idasanutlin in Participants With Stage IV or Unresectable Recurrent Estrogen Receptor Positive Breast Cancer · 87 trials list this drug (22 active) | — | — | Malignant Breast Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03264066Phase 2 · completed A Study to Investigate the Efficacy and Safety of Cobimetinib Plus Atezolizumab in Participants With Solid Tumors · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03224208Phase 2 · terminated Vemurafenib Plus Cobimetinib in Advanced or Metastatic Melanoma Patients · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02303951Phase 2 · terminated Neoadjuvant Vemurafenib + Cobimetinib + Atezolizumab in Melanoma: NEO-VC · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01656642Phase 1 · completed A Phase 1b Study of Atezolizumab in Combination With Vemurafenib or Vemurafenib Plus Cobimetinib in Participants With BRAFV600-Mutation Positive Metastatic Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01988896Phase 1 · completed Study of Atezolizumab in Combination With Cobimetinib in Participants With Locally Advanced or Metastatic Solid Tumors · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02788279Phase 3 · completed A Study to Investigate Efficacy and Safety of Cobimetinib Plus Atezolizumab and Atezolizumab Monotherapy Versus Regorafenib in Participants With Metastatic Colorectal Adenocarcinoma (COTEZO IMblaze370) · 87 trials list this drug (22 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02768207Phase 2 · completed A Study to Detect V-Raf Murine Sarcoma Viral Oncogene Homolog B1 (BRAF) V600 Mutation on Cell-Free Deoxyribonucleic Acid (cfDNA) From Plasma in Participants With Advanced Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02876224Phase 1 · completed Study of Cobimetinib in Combination With Atezolizumab and Bevacizumab in Participants With Gastrointestinal and Other Tumors · 87 trials list this drug (22 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01271803Phase 1 · completed A Study of Vemurafenib and GDC-0973 (Cobimetinib) in Participants With BRAFV600E Mutation-Positive Metastatic Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01813214Phase 2 · terminated The Effects of Vemurafenib + Cobimetinib on Immunity in Patients With Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03139513completed A Study of Adult Participants With BRAF V600 Mutation-Positive Advanced Melanoma Treated With Cobimetinib (Cotellic®) During the French Early Access Program (Temporary Authorization for Use [TAU]) · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02457793Phase 1 · completed A Study of the Safety, Tolerability, and Effects of Cobimetinib and GDC-0994 in Patients With Locally Advanced or Metastatic Solid Tumors · 87 trials list this drug (22 active) | — | — | Lung Non-Small Cell Carcinoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT03340558Phase 2 · withdrawn Atezolizumab Monotherapy vs Atezolizumab Plus Cobimetinib in Liver Metastases From Colorectal Cancer · 87 trials list this drug (22 active) | — | — | Malignant Colorectal Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01495988Phase 2 · terminated Trial of Vemurafenib/Cobimetinib With or Without Bevacizumab in Patients With Stage IV BRAFV600 Mutant Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02230306Phase 2 · terminated Phase II Study of Cobimetinib in Combination With Vemurafenib in Active Melanoma Brain Metastases · 87 trials list this drug (22 active) | — | — | not mapped | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00996892Phase 1 · terminated Safety, Tolerability and Pharmacokinetics of Cobimetinib in Combination With Pictilisib in Patients With Locally Advanced or Metastatic Solid Tumors · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT02427893Phase 3 · withdrawn Trial of Vemurafenib and Cobimetinib in Patients With Advanced BRAFV600 Mutant Melanoma · 87 trials list this drug (22 active) | — | — | Melanoma | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01974258Phase 1 · withdrawn Safety, Tolerability, and Pharmacokinetics of Onartuzumab Combined With Vemurafenib and/or Cobimetinib in Cancer Patients · 87 trials list this drug (22 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT00467779Phase 1 · completed Study of Cobimetinib in Participants With Solid Tumors · 87 trials list this drug (22 active) | — | — | Solid Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01986166Phase 1 · completed A Study of MEHD7945A and Cobimetinib in Patients With Locally Advanced or Metastatic Cancers With Mutant KRAS · 87 trials list this drug (22 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |
| → studied in | NCT01562275Phase 1 · completed A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0973 in Combination With GDC-0068 When Administered in Participants With Locally Advanced or Metastatic Solid Tumors · 87 trials list this drug (22 active) | — | — | Neoplasm | 1 | Observed | clinicaltrials | graph → |